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NMR Compound 1 S18 S4 resolution mass spectra (HRMS) were run on an ABSCIEX Triple TOF 5600 Mass
Spectrometer. Optical rotations were performed on a JASCO P-2000 polarimeter. Nuclear magnetic resonance (NMR) spectra were recorded on a Bruker AM 300 MHz (1D spectra) or
Bruker AM 500 MHz (2D spectra) instrument, using CDCl 3 as deuterated solvent with reference to tetramethylsilane as internal standard, at 297 K. Coupling constants are given in Hertz (Hz). with a 1 mL/min flow rate and detection at 214 nm.
Semi-preparative RP-HPLC was performed using a Waters Delta 600 system (Milford, Massachusetts, USA; model 600 controller, 490E UV detector). Purifications were achieved using Vydac ® C4 or C18 preparative columns (10 µm, 10 mm i.d. × 250 mm) using a stated gradient quoted as % solvent B at 4 mL/min flow rate, and detection at 214 nm. Fractions containing pure compound were pooled and lyophilized overnight.
Preparative RP-HPLC was performed on a Shimadzu (Kyoto, Japan) instrument (LC-20AP liquid chromatograph, CMB-20A communication bus module, SPD-20 UV-vis detector, FRC-10A fraction collector), with C18 or C4 Grace Vydac ® (Columbia, Maryland, USA) columns (10 µm, 22 mm internal diameter × 250 mm,) using a stated gradient quoted as % solvent B with a 20 mL/min flow rate and detection at 214 nm.
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Methyl 6-hydroxyhexanoate (3):
Concentrated sulfuric acid (1 mL) was added to a solution of -caprolactone (10.00 g, 87.61 mmol) in CH 3 OH (30 mL) and the mixture was stirred at room temperature for 30 min. The mixture was diluted with Et 2 O (100 mL), and the organic phase was washed with sat. 
, methyl 6-hydroxyhexanoate 3 (1.71 g, 11.69 mmol), CH 2 Cl 2 (30 mL) and molecular sieves (4 Å, approx. 4 g) were stirred under N 2 at room temperature overnight. Silver(I) oxide (3.61 g, 15.58 mmol) was added and the mixture was stirred at room temperature for 5 h, which resulted in a mixture of orthoester byproduct 4 and the desired glycosylation product 5. TMSOTf (0.14 mL, 0.79 mmol) was added to the reaction mixture and, after 5 min stirring at room temperature, the solids were removed by filtration through a bed of Celite ® . The filtrate was washed with sat. NaHCO 3 (2 x 50 mL), dried (MgSO 4 ) and evaporated. The residue was dissolved in CH 3 OH (50 mL), Na (0.30 g, 13 mmol) was added and the mixture was stirred under N 2 for 20 min. The mixture was neutralized using Amberlite ® IR-120H ion-exchange resin, filtered and the solvent evaporated. Water (50 mL) was added to the residue and the aqueous phase was washed with Et 2 O (2 x 50 mL). The aqueous solution was lyophilized and the residue was dissolved in dry THF (50 mL). Sodium hydride (57-63% oil dispersion, 3.12 g, 77.90 mmol) was added and the mixture stirred at room temperature under N 2 for 20 min. Following addition of propargyl S6 bromide (80% in toluene, 13.02 mL, 116.85 mmol), the reaction mixture was stirred at room temperature overnight. Sodium hydroxide (2 M, 50 mL) was added and the mixture was stirred at room temperature for 1 h. The reaction mixture was transferred to a separating funnel and the basic aqueous phase was washed with Et 2 O (3 x 50 mL). The basic phase was acidified with glacial acetic acid and the product was extracted into CH 2 Cl 2 (3 x 50 mL). The organic phase was washed with water (50 mL 
Synthesis of Peptides and Lipopeptides
Stepwise SPPS (manual and microwave-assisted) was performed using rink amide MBHA resin (substitution ratio: 0.60 mmol/g) with standard Fmoc SPPS chemistry: The J8 B cell epitope (QAEDKVKQSREAKKQVEKALKQLEDKVQ) was synthesized using the above manual standard Fmoc SPPS conditions. Azidoacetic acid [5] was coupled in triplicate to the N-terminus of the J8 B cell epitope using the same conditions as those used 
Glyco-lipopeptide (9):
The LLCP lipopeptide (K(C12)GK(C12)K(C12)G) was synthesized using microwaveassisted standard Fmoc SPPS conditions. Carbohydrate carrier 1 (2.5 equiv.) was preactivated with HBTU (2.4 equiv.) and DIPEA (4.0 equiv.), and coupled to the LLCP lipopeptide with microwave assistance (2 x 10 min at 70 ºC), to give glyco-lipopeptide 9.
Following cleavage from the resin and precipitation, the crude glyco-lipopeptide 9 was dissolved in a minimum volume of DMF, diluted with solvent A and B (1:1, 100 mL), and lyophilized. Glyco-lipopeptide 9 was used without purification in the proceeding step. HPLC 
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Glyco-lipopeptide (11):
The T-helper-LLCP lipopeptide (KFVAAWTLKAA-K(C12)GK(C12)K(C12)G) was synthesized using microwave-assisted standard Fmoc SPPS conditions. Carbohydrate carrier 1 was coupled as described above, to give glyco-lipopeptide 11. Following cleavage from the resin and precipitation, the crude glyco-lipopeptide 11 was dissolved in a minimum volume of DMF, diluted with solvent A and B (1:1, 100 mL), and lyophilized. Glyco-lipopeptide 11 was used without purification in the proceeding step. HPLC analysis (C4 column): t R = 33.50 ELSD detection 800 900 1000 1100 1200 1300 1400 1500 1600 1700 1800 1900 2000 2100 2200 2300 2400 2500 2600 2700 2800 2900 3000 m/z, amu 5000.00 
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Analytical RP-HPLC chromatograms of Vaccine Candidate 12
Blue trace = % solvent B; 5 min at 0%, 0-20% over 5 min, 20-60% over 30 min. 
